The tumor microenvironment of ALK-positive NSCLC suggests a poorly immunogenic “immune desert” of ALK-positive NSCLC, preventing the successful use of immune checkpoint inhibitors [52]; most trials with immunotherapy in lung cancer have excluded patients with ALK-rearranged NSCLC, due to less efficacy of immunotherapy in this group [53]. This evidence concerns the gene ALK and lung carcinoma.